What is Compass Pathways?
Compass Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation. The firm is primarily focused on developing a new model of psilocybin therapy, centered on its proprietary synthetic formulation, COMP360. By integrating this pharmacological approach with structured psychological support, the company aims to provide a scalable solution for individuals suffering from mental health challenges that remain unresponsive to current standard-of-care treatments. Its market position is defined by a rigorous commitment to clinical validation and the pursuit of transformative outcomes in psychiatric care.
How much funding has Compass Pathways raised?
Compass Pathways has raised a total of $578.5M across 5 funding rounds:
Series A
$35.5M
Series B
$80M
Stock Offering
$128M
Debt
$50M
Other Financing Round
$285M
Series A (2018): $35.5M, investors not publicly disclosed
Series B (2020): $80M led by ATAI Life Sciences, Soleus Capital, McQuade Center for Strategic Research and Development, Perceptive Advisors, Skyviews Life Science, Founders Fund, Camden Partners Nexus, and Able Partners
Stock Issuance/Offering (2020): $128M, investors not publicly disclosed
Debt (2023): $50M featuring Hercules Capital
Other Financing Round (2023): $285M backed by Aisling Capital, TCG Crossover, Logos Capital Partners Sa rl, and Vivo Capital
Key Investors in Compass Pathways
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with a strong focus on biopharmaceutical development.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and supporting breakthrough therapies that have the potential to transform healthcare.
Logos Capital Partners Sa rl
Logos Capital provides operational and financial leadership, focusing on business discipline and strategic support for companies within the healthcare and management sectors.
What's next for Compass Pathways?
With the recent infusion of $285M, Compass Pathways is well-positioned to accelerate its late-stage clinical trials and expand its operational footprint. The strategic focus will likely remain on the refinement of the COMP360 delivery model and the preparation for potential commercialization pathways. As the company moves forward, it will continue to leverage its robust balance sheet to support long-term research initiatives, aiming to redefine the standard of care for mental health globally. The ongoing support from specialized life sciences investors provides the necessary runway to navigate the final phases of clinical development and regulatory approval, ultimately aiming to bring a novel therapeutic paradigm to the global market.
See full Compass Pathways company page
